PharmaCan Capital invests in the Whistler Medical Marijuana Company

Dec. 16, 2013

PharmaCan Capital is pleased to announce that it has made an investment in the Whistler Medical Marijuana Company (WMMC).  “WMMC’s Founder and President Christopher Pelz has assembled an outstanding team and we are extremely confident that the company will be granted a license by Health Canada for the commercial production and distribution of medical marihuana under the MMPR in the near future”, said PharmaCan’s CEO Paul Rosen.

“Adding the Whistler brand to our portfolio is an important step for PharmaCan as we continue to execute on our strategy of assembling a high quality portfolio of companies that are leading the development of the medical cannabis industry in Canada.  This is the second investment made by PharmaCan and we are actively evaluating additional investments in companies that provide services, information and products to patients, growers and health care providers” commented Mr. Rosen.


The Whistler Medical Marijuana Company is a locally owned and operated business in Whistler B.C., a place where “alternative” and “leading edge” are part of the community fabric. The focus is on producing the highest quality crops of medicinal marijuana, grown organically, on a small scale, sourced from leading pioneer seed stock from around the world.

The goal of the Whistler Medical Marijuana Company is to develop medical marijuana at a world class level and to lead the development of pioneer strains and growing methods that will help patients seeking to make an informed choice.